- Season: Everbearing
- Main characteristic/s: Very sweet flavour, excellent shelf life
- Breeder: Marionnet SAS, France
Characteristics of Mariguette® (Marionnet 99)
Cropping Season- Very sweet flavoured berries with a pleasant fragrance
- High Brix levels
- Excellent shelf life and berry firmness
- Attractive, glossy bright red berries
- High fruit yields
Mariguette® is an everbearing strawberry cropping from the beginning of July.
Fruit Quality
The berries are large and oblong in shape, orange-red in colour with a very shiny skin finish. The flavour has good sweetness with a high Brix index and a subtler fragrance than Mara des Bois. The shelf life and berry firmness are excellent.
Fruit Yield
Mariguette® has a high yield potential, better than Charlotte, particularly in spring production from a tray plant.
Plant Characteristics
Plants are fairly robust with cupped spoon-like leaves. Mariguette® is well adapted to substrate production using tray plants.
Plant Supply
Mariguette® (Marionnet 99) is protected under Australia PBR Application No. 2016/380; Canada PBR Grant No. 5842; Morocco PBR Application No. 526/14. The propagation and sale of plants, or parts of plants, of Mariguette® without a licence is prohibited. Only Propagation Licence holders can propagate and receive propagation grade material (and not Sales or Growing-on Transformation Licence holders). Mariguette® is available from the following licensed propagators:
Propagation Licence Holders
- Country
- Company
- Website
- Telephone
- FR
- Marionnet SAS
- Visit website
- +33 254 987 103
- Send email
Sales Licence Holders (Commercial Growers)
- Country
- Company
- Website
- Telephone
Sales Licence Holders (Amateur/Garden Market ONLY)
- Country
- Company
- Website
- Telephone
- UK
- D.T. Brown Seeds T/A Fothergill's Seeds Ltd
- Visit website
- +44 01638 751 161
- None available
- UK
- Pomona Fruits Ltd
- Visit website
- +44 01255 440 410
- Send email
Growing-on / Transformation Licence Holders
- Country
- Company
- Website
- Telephone
Trial Results
Raised bed trials: